Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 44, Issue , 2013, Pages 94-99

  Mustapic, Maja ^a   Presecki, Paola ^b   Pivac, Nela ^a   Mimica, Ninoslav ^c   Hof, Patrick R ^d   Simic, Goran ^e   Folnegovic Smalc, Vera ^c   Muck Seler, Dorotea ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b brankarestek petrovic pbsvihr   (Croatia)

^c Psychiatric Hospital Vrap e   (Croatia)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Alzheimer's disease; Cognitive decline; DBH gene polymorphisms; Dopamine beta hydroxylase; Plasma DBH activity

Indexed keywords

APOLIPOPROTEIN E; DOPAMINE BETA MONOOXYGENASE;

AGED; ALZHEIMER DISEASE; APOE GENE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOPAMINE BETA HYDROXYLASE GENE; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; DOPAMINE BETA-HYDROXYLASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES;

EID: 84874523754     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.02.002     Document Type: Article

References (57)

1. Alzheimer's Association 2010 Alzheimer's disease facts and figures. Alzheimers Dement 2010, 6:158-194.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders: DSM-IV 1994, American Psychiatric Association, Washington, DC. 4th ed.
3. Arato M., Bagdy G., Blumel F., Perenyi A., Rihmer Z. Reduced serum dopamine-beta-hydroxylase activity in paranoid schizophrenics. Pharmacopsychiatria 1983, 16:19-22.
4. Baron M., Gruen R., Levitt M., Kane J. Neuroleptic drug effect on plasma dopamine-beta-hydroxylase in schizophrenia. Neuropsychobiology 1982, 8:312-314.
5. Bhaduri N., Mukhopadhyay K. Correlation of plasma dopamine beta-hydroxylase activity with polymorphisms in DBH gene: a study on Eastern Indian population. Cell Mol Neurobiol 2008, 28:343-350.
6. Boban M., Malojcic B., Mimica N., Vukovic S., Zrilic I., Hof P.R., et al. The reliability and validity of the Mini-Mental State Examination in the elderly Croatian population. Dement Geriatr Cogn Disord 2012, 33:385-392.
7. Bourdelat-Parks B.N., Anderson G.M., Donaldson Z.R., Weiss J.M., Bonsall R.W., Emery M.S., et al. Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacology (Berl) 2005, 183:72-80.
8. Burke W.J., Li S.W., Schmitt C.A., Xia P., Chung H.D., Gillespie K.N. Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer's disease: mechanism of neuron death. Brain Res 1999, 816:633-637.
9. Chen Y., Wen G., Rao F., Zhang K., Wang L., Rodriguez-Flores J.L., et al. Human dopamine beta-hydroxylase (DBH) regulatory polymorphism that influences enzymatic activity, autonomic function, and blood pressure. J Hypertens 2010, 28:76-86.
10. Combarros O., Warden D.R., Hammond N., Cortina-Borja M., Belbin O., Lehmann M.G., et al. The dopamine beta-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project. BMC Med Genet 2010, 11:162.
11. Counts S.E., Mufson E.J. Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J Neurochem 2010, 113:649-660.
12. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983, 219:1184-1190.
13. Cross A.J., Crow T.J., Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J (Clin Res Ed) 1981, 282:93-94.
14. Cubells J.F., Zabetian C.P. Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology. Psychopharmacology (Berl) 2004, 174:463-476.
15. Cummings J.L. Alzheimer's disease. N Engl J Med 2004, 351:56-67.
16. Elrod R., Peskind E.R., DiGiacomo L., Brodkin K.I., Veith R.C., Raskind M.A. Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am J Psychiatry 1997, 154:25-30.
17. Feinstein D.L., Heneka M.T., Gavrilyuk V., Dello Russo C., Weinberg G., Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int 2002, 41:357-365.
18. Fitzgerald P.J. Is elevated norepinephrine an etiological factor in some cases of Alzheimer's disease?. Curr Alzheimer Res 2010, 7:506-516.
19. Folstein M.F., Folstein S.E., McHugh P.R. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
20. Forstl H., Levy R., Burns A., Luthert P., Cairns N. Disproportionate loss of noradrenergic and cholinergic neurons as cause of depression in Alzheimer's disease - a hypothesis. Pharmacopsychiatry 1994, 27:11-15.
21. Friedman M.J., Stolk J.M., Harris P.Q., Cooper T.B. Serum dopamine-beta-hydroxylase activity in depression and anxiety. Biol Psychiatry 1984, 19:557-570.
22. Garcia-Alloza M., Gil-Bea F.J., Diez-Ariza M., Chen C.P., Francis P.T., Lasheras B., et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 2005, 43:442-449.
23. Giacobini E. Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry 2003, 18:S1-S5.
24. Giubilei F., Calderaro C., Antonini G., Sepe-Monti M., Tisei P., Brunetti E., et al. Increased lymphocyte dopamine beta-hydroxylase immunoreactivity in Alzheimer's disease: compensatory response to cholinergic deficit?. Dement Geriatr Cogn Disord 2004, 18:338-341.
25. Grudzien A., Shaw P., Weintraub S., Bigio E., Mash D.C., Mesulam M.M. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging 2007, 28:327-335.
26. Heneka M.T., O'Banion M.K. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007, 184:69-91.
27. Heneka M.T., Nadrigny F., Regen T., Martinez-Hernandez A., Dumitrescu-Ozimek L., Terwel D., et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A 2010, 107:6058-6063.
28. Herrmann N., Lanctot K.L., Khan L.R. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 2004, 16:261-276.
29. Hoogendijk W.J., Feenstra M.G., Botterblom M.H., Gilhuis J., Sommer I.E., Kamphorst W., et al. Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann Neurol 1999, 45:82-91.
30. Hosking L., Lumsden S., Lewis K., Yeo A., McCarthy L., Bansal A., et al. Detection of genotyping errors by Hardy-Weinberg equilibrium testing. Eur J Hum Genet 2004, 12:395-399.
31. Kim C.H., Zabetian C.P., Cubells J.F., Cho S., Biaggioni I., Cohen B.M., et al. Mutations in the dopamine beta-hydroxylase gene are associated with human norepinephrine deficiency. Am J Med Genet 2002, 108:140-147.
32. Lerner P., Goodwin F.K., van Kammen D.P., Post R.M., Major L.F., Ballenger J.C., et al. Dopamine-beta-hydroxylase in the cerebrospinal fluid of psychiatric patients. Biol Psychiatry 1978, 13:685-694.
33. Lewis E.J., Asnani L.P. Soluble and membrane-bound forms of dopamine beta-hydroxylase are encoded by the same mRNA. J Biol Chem 1992, 267:494-500.
34. Lyness S.A., Zarow C., Chui H.C. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging 2003, 24:1-23.
35. Mateo I., Infante J., Rodriguez E., Berciano J., Combarros O., Llorca J. Interaction between dopamine beta-hydroxylase and interleukin genes increases Alzheimer's disease risk. J Neurol Neurosurg Psychiatry 2006, 77:278-279.
36. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
37. McMillan P.J., White S.S., Franklin A., Greenup J.L., Leverenz J.B., Raskind M.A., et al. Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Res 2011, 1373:240-252.
38. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
39. Mustapic M., Pivac N., Kozaric-Kovacic D., Dezeljin M., Cubells J.F., Muck-Seler D. Dopamine beta-hydroxylase (DBH) activity and -1021C/T polymorphism of DBH gene in combat-related post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:1087-1089.
40. Nagatsu T., Udenfriend S. Photometric assay of dopamine-hydroxylase activity in human blood. Clin Chem 1972, 18:980-983.
41. O'Connor D.T., Cervenka J.H., Stone R.A., Levine G.L., Parmer R.J., Franco-Bourland R.E., et al. Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson's disease and congenital dopamine beta-hydroxylase deficiency. Clin Sci (Lond) 1994, 86:149-158.
42. Ogihara T., Nugent C.A., Shen S.W., Goldfein S. Serum dopamine-beta-hydroxylase activity in parents and children. J Lab Clin Med 1975, 85:566-573.
43. Paclt I., Koudelova J. Changes of dopamine-beta-hydroxylase activity during ontogenesis in healthy subjects and in an experimental model (rats). Physiol Res 2004, 53:661-667.
44. Perry E.K., Tomlinson B.E., Blessed G., Perry R.H., Cross A.J., Crow T.J. Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease. J Neurol Sci 1981, 51:279-287.
45. Raskind M.A., Peskind E.R., Holmes C., Goldstein D.S. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biol Psychiatry 1999, 46:756-765.
46. Schroeder J.P., Cooper D.A., Schank J.R., Lyle M.A., Gaval-Cruz M., Ogbonmwan Y.E., et al. Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine beta-hydroxylase. Neuropsychopharmacology 2010, 35:2440-2449.
47. Szot P., White S.S., Greenup J.L., Leverenz J.B., Peskind E.R., Raskind M.A. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J Neurosci 2006, 26:467-478.
48. Tang Y., Anderson G.M., Zabetian C.P., Kohnke M.D., Cubells J.F. Haplotype-controlled analysis of the association of a non-synonymous single nucleotide polymorphism at DBH (+1603C→T) with plasma dopamine beta-hydroxylase activity. Am J Med Genet B Neuropsychiatr Genet 2005, 139B:88-90.
49. Tang Y.L., Epstein M.P., Anderson G.M., Zabetian C.P., Cubells J.F. Genotypic and haplotypic associations of the DBH gene with plasma dopamine beta-hydroxylase activity in African Americans. Eur J Hum Genet 2007, 15:878-883.
50. Weinshenker D. Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr Alzheimer Res 2008, 5:342-345.
51. Weinshilboum R.M., Thoa N.B., Johnson D.G., Kopin I.J., Axelrod J. Proportional release of norepinephrine and dopamine-hydroxylase from sympathetic nerves. Science 1971, 174:1349-1351.
52. Weinshilboum R.M., Raymond F.A., Elveback L.R., Weidman W.H. Serum dopamine-beta-hydroxylase activity: sibling-sibling correlation. Science 1973, 181:943-945.
53. Wenk G.L. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry 2003, 64(Suppl. 9):7-10.
54. Wenk G.L., McGann K., Hauss-Wegrzyniak B., Rosi S. The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer's disease. Neuroscience 2003, 121:719-729.
55. Zabetian C.P., Anderson G.M., Buxbaum S.G., Elston R.C., Ichinose H., Nagatsu T., et al. A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am J Hum Genet 2001, 68:515-522.
56. Zabetian C.P., Buxbaum S.G., Elston R.C., Kohnke M.D., Anderson G.M., Gelernter J., et al. The structure of linkage disequilibrium at the DBH locus strongly influences the magnitude of association between diallelic markers and plasma dopamine beta-hydroxylase activity. Am J Hum Genet 2003, 72:1389-1400.
57. Zhou X., Espey M.G., Chen J.X., Hofseth L.J., Miranda K.M., Hussain S.P., et al. Inhibitory effects of nitric oxide and nitrosative stress on dopamine-beta-hydroxylase. J Biol Chem 2000, 275:21241-21246.